ArticleMolecular nutrition & food research2020
Flavone Hispidulin Stimulates Glucagon-Like Peptide-1 Secretion and Ameliorates Hyperglycemia in Streptozotocin-Induced Diabetic Mice.
Article in Molecular nutrition & food research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Nutraceutical Eriocitrin (Eriomin) Reduces Hyperglycemia by Increasing Glucagon-Like Peptide 1 and Downregulates Systemic Inflammation: A Crossover-Randomized Clinical Trial.Journal of medicinal food · 2022Trial
- Hispidulin: A potential antihyperglycemic and anti-oxidant agent-mechanistic insights into its modulatory effects on PI3K, AKT, mTOR, IRS1, GSK-3β, and GLUT-4 pathways through in vitro and in vivo studies.Iranian journal of basic medical sciences · 2026Article
- Phytochemical Constituent of Devil Weed (Molecules (Basel, Switzerland) · 2025Article
- Dual therapeutic potential of Scoparia dulcis in combating hyperglycemia and inflammation in diabetes through network pharmacology and in silico analysis.Scientific reports · 2025Article
- Metabolomic profiles and health-promoting potential ofFrontiers in plant science · 2025Article
- Exploring the Antidiabetic Potential ofPlants (Basel, Switzerland) · 2024Article
- Potential Role of Phytochemicals as Glucagon-like Peptide 1 Receptor (GLP-1R) Agonists in the Treatment of Diabetes Mellitus.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Exploring Folklore Ecuadorian Medicinal Plants and Their Bioactive Components Focusing on Antidiabetic Potential: An Overview.Plants (Basel, Switzerland) · 2024Review
- Flavonoids fromADMET & DMPK · 2024Review
- The Potential of the Flavonoid Content ofMetabolites · 2023Review
- Could Naringenin Participate as a Regulator of Obesity and Satiety?Molecules (Basel, Switzerland) · 2023Review
- Identification of Genipin as a Potential Treatment for Type 2 Diabetes.International journal of molecular sciences · 2023Article
- Extraction Optimization, Preliminary Identification, and Bioactivities in Corn Silk.Evidence-based complementary and alternative medicine : eCAM · 2023Article
- An olive-derived elenolic acid stimulates hormone release from L-cells and exerts potent beneficial metabolic effects in obese diabetic mice.Frontiers in nutrition · 2022Article
- Improvement of Glucose Tolerance by Food Factors Having Glucagon-Like Peptide-1 Releasing Activity.International journal of molecular sciences · 2021Review
- The Emerging Role of Polyphenols in the Management of Type 2 Diabetes.Molecules (Basel, Switzerland) · 2021Review
- Histopathological Profiles of Rats (Veterinary medicine international · 2021Article
- Hypoglycemic Effect of Prolamin from Cooked Foxtail Millet (Nutrients · 2020Article
- Biochemical Investigation of Therapeutic Potentials of Plant-Based Bioactive Compounds as Stimulators of Glucagon like peptide-1 Secretion.Dose-response : a publication of International Hormesis SocietyArticle
- Anti-inflammation and Anti-insulin Resistance of a Compound from VietnameseIranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
scopeLoss of functional β-cell mass is central for the deterioration of glycemic control in diabetes. The incretin hormone glucagon-like peptide-1 (GLP-1) plays a critical role in maintaining glycemic homeostasis via potentiating glucose-stimulated insulin secretion and promoting β-cell mass. Agents that can directly promote GLP-1 secretion, thereby increasing insulin secretion and preserving β-cell mass, hold great potential for the treatment of T2D. METHODS AND
resultsGluTag L-cells, INS832/13 cells, and mouse ileum crypts and islets are cultured for examining the effects of flavone hispidulin on GLP-1 and insulin secretion. Mouse livers and isolated hepatocytes are used for gluconeogenesis. Streptozotocin-induced diabetic mice are treated with hispidulin (20 mg kg
conclusionThese findings suggest that Hispidulin may be a novel dual-action anti-diabetic compound via stimulating GLP-1 secretion and suppressing hepatic glucose production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.